

**DIVI'S LABORATORIES LIMITED**

UNAUDITED FINANCIAL RESULTS (STANDALONE)  
FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2012

(₹. in Lakhs)

Sl No.	Particulars	STANDALONE					
		Unaudited					Audited
		Quarter ended			Half year ended		Year Ended
	30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	31.03.2012	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
<b>1</b>	<b>Income from operations</b>						
	(a) Net Sales/Income from operations (Net of Excise Duty)	<b>47260</b>	46841	35367	<b>94101</b>	71495	183949
	(b) Other Operating Income	<b>114</b>	110	74	<b>224</b>	115	544
	<b>Total Income from operations (net)</b>	<b>47374</b>	46951	35441	<b>94325</b>	71610	184493
<b>2</b>	<b>Expenses</b>						
	a. Cost of materials consumed	<b>23131</b>	17257	14956	<b>40388</b>	32931	77177
	b. Purchases of stock-in-trade	<b>0</b>	0	0	<b>0</b>	0	10
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(6978)</b>	(1174)	(468)	<b>(8152)</b>	(4094)	(1066)
	d. Employee benefits expense	<b>4337</b>	4845	3237	<b>9182</b>	6533	14516
	e. Depreciation and amortization expense	<b>1879</b>	1748	1520	<b>3627</b>	2920	6203
	f. Other Expenses	<b>10385</b>	6869	5081	<b>15176</b>	10476	24369
	<b>Total Expenses</b>	<b>32754</b>	29545	24326	<b>60221</b>	48766	121209
<b>3</b>	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items (1-2)</b>	<b>14620</b>	17406	11115	<b>34104</b>	22844	63284
<b>4</b>	<b>Other Income</b>	<b>847</b>	4066	2277	<b>2835</b>	3586	6576
<b>5</b>	<b>Profit from ordinary activities before finance costs &amp; exceptional Items (3+4)</b>	<b>15467</b>	21472	13392	<b>36939</b>	26430	69860
<b>6</b>	Finance Costs	<b>31</b>	41	76	<b>72</b>	121	374
<b>7</b>	<b>Profit from ordinary activities after finance costs but before exceptional Items (5-6)</b>	<b>15436</b>	21431	13316	<b>36867</b>	26309	69486
<b>8</b>	Exceptional items	<b>0</b>	0	0	<b>0</b>	0	0
<b>9</b>	<b>Profit from ordinary activities before Tax (7-8)</b>	<b>15436</b>	21431	13316	<b>36867</b>	26309	69486
<b>10</b>	Tax Expense	<b>3639</b>	4693	2711	<b>8332</b>	5445	14889
<b>11</b>	<b>Net Profit from ordinary activities after Tax (9-10)</b>	<b>11797</b>	16738	10605	<b>28535</b>	20864	54597
<b>12</b>	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	<b>0</b>		0

<b>13</b>	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>11797</b>	16738	10605	<b>28535</b>	20864	54597
<b>14</b>	Share of profit / (loss) of associates	0	0	0	0	0	0
<b>15</b>	Minority Interest	0	0	0	0	0	0
<b>16</b>	<b>Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)</b>	<b>11797</b>	16738	10605	<b>28535</b>	20864	54597
<b>17</b>	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	<b>2655</b>	2655	2653	<b>2655</b>	2653	2655
<b>18</b>	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						214825
<b>19.i</b>	<b>Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):</b>						
	a) Basic	<b>8.89</b>	12.61	8.00	<b>21.50</b>	15.73	41.15
	b) Diluted	<b>8.89</b>	12.61	7.99	<b>21.50</b>	15.73	41.15
<b>19.ii</b>	<b>Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):</b>						
	a) Basic	<b>8.89</b>	12.61	8.00	<b>21.50</b>	15.73	41.15
	b) Diluted	<b>8.89</b>	12.61	7.99	<b>21.50</b>	15.73	41.15

<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
<b>1</b>	Public shareholding - No. of shares - Percentage of shareholding	<b>63512190</b> <b>47.85%</b>	63512190 47.85%	63454450 47.83%	<b>63512190</b> <b>47.85%</b>	63454450 47.83%	63512190 47.85%
<b>2</b>	Promoters and promoter group shareholding <b>a) pledged / encumbered</b> <b>b) non-encumbered:</b> - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	<b>Nil</b> <b>69222100</b> <b>100%</b> <b>52.15%</b>	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.17%	<b>Nil</b> <b>69222100</b> <b>100%</b> <b>52.15%</b>	Nil 69222100 100% 52.17%	Nil 69222100 100% 52.15%

	<b>Particulars</b>	<b>Quarter ended 30-09-2012</b>
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	7
	Disposed off during the quarter	7
	Remaining unresolved at the end of the quarter	Nil

**Statement of Assets and Liabilities:**

(₹. in lakhs)

	Particulars	STANDALONE	
		As At	
		30.09.2012	31.03.2012
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' Funds</b>		
	a) Share Capital	2655	2655
	b) Reserves and Surplus	243360	214825
	c) Money received against share warrants	0	0
	<b>Sub-total – Shareholders' funds</b>	<b>246015</b>	<b>217480</b>
<b>2</b>	<b>Share application money pending allotment</b>	<b>0</b>	<b>0</b>
<b>3</b>	<b>Minority interest</b>	<b>0</b>	<b>0</b>
<b>4</b>	<b>Non-current liabilities</b>		
	a) Long-term borrowings	256	256
	b) Deferred tax liabilities (net)	7289	6729
	c) Other long-term liabilities	612	625
	d) Long-term provisions	171	165
	<b>Sub-total – Non-current liabilities</b>	<b>8328</b>	<b>7775</b>
<b>5</b>	<b>Current Liabilities</b>		
	a) Short-term borrowings	4019	5020
	b) Trade payables	13592	15731
	c) Other current liabilities	10560	13470
	d) Short-term provisions	127	20821
	<b>Sub-total – Current liabilities</b>	<b>28298</b>	<b>55042</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>282641</b>	<b>280297</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	a) Fixed assets	105130	92018
	b) Goodwill on consolidation	0	0
	c) Non-current investments	282	282
	d) Deferred tax assets (net)	0	0
	e) Long-term loans and advances	11444	12469
	f) Other non-current assets	155	393
	<b>Sub-total – Non-current assets</b>	<b>117011</b>	<b>105162</b>
<b>2</b>	<b>Current assets</b>		
	a) Current investments	35405	47704
	b) Inventories	76937	65097
	c) Trade receivables	42155	53447
	d) Cash and cash equivalents	1557	2182
	e) Short-term loans and advances	9223	6413
	f) Other current assets	353	292
	<b>Sub-total – Current assets</b>	<b>165630</b>	<b>175135</b>
	<b>TOTAL - ASSETS</b>	<b>282641</b>	<b>280297</b>

**NOTES:**

1. The above results for the quarter ended 30<sup>th</sup> September 2012, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 3<sup>rd</sup> November, 2012 and were subjected to 'limited review' by the Auditors.

2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. As approved by the Members of the company at the 22<sup>nd</sup> Annual general Meeting on 6<sup>th</sup> August, 2012, the company has disbursed on 21<sup>st</sup> August, 2012 a dividend of ₹ 13 per equity share of Rs.2 each for the year ended 31<sup>st</sup> March, 2012, amounting to Rs. 20055 lakhs (inclusive of dividend tax)
5. Other Expenses for the current quarter includes Forex loss of ₹ 2078 lakhs.
6. Figures for the previous year/period have been regrouped or recasted, wherever necessary.

for Divi's Laboratories Limited

Place: Hyderabad  
Date: 3<sup>rd</sup> November, 2012

Dr. Murali K. Divi  
Chairman & Managing Director